Redeye is again positively surprised to see CTEK beating our estimates on the top line and profitabi...
Redeye comments on Fable Media Group’s Q3 results, which came in somewhat lower than expected in ter...
Redeye returns with an update following Alzecure's Q3 report.
Signs SEK 132m expansion order from Swedish Space Corporation New run-rate of ~SEK 250m is 37% above...
Redeye comments on Thunderful Group’s Q3’24 report, which was weaker than expected, primarily due to...
Redeye comments on Embracer’s Q2-results which were somewhat weaker than expected, owing mainly to P...
Redeye updates its view on Lifecare following its Q3 report.
Redeye is encouraged by the new management in Sivers, guiding for a long-term ambition of reaching a...
Redeye comments on Better Collective’s Q3-results which were in line with the preliminary announceme...
Redeye updates on Gentoo Media following Q3-results where we have made limited changes to estimates ...
Solid outlook remains for an acceleration in Q4 Limited sales and adj.
Redeye provides an update on Scandinavian ChemoTech following the Q3 2024 report.
AcuCort (”AcuCort” eller ”Bolaget”) meddelade den 13 november år 2024 att samtliga patienter har gen...
Irisity AB (”Irisity” or ”the Company”) is a leading provider of AI-driven video analytics solutions...
Q3 in line with pre-announcement Strong Q4 on the cards; 20% sales growth q-o-q No change to FY guid...
Nu är guldproduktionen i Fäbodtjärn i gång. Gruvan invigdes i maj och i augusti sköts den första mal...
Redeye sees a Q3 report from BrightBid on the soft side regarding ARR growth.
Redeye comments on yesterday’s news that Kancera will concentrate its resources on cardiovascular di...
Redeye saw a Q3 report in which sales and gross margins slightly exceeded our estimates.
Redeye views the Q3 report as relatively uneventful, apart from the apparent successful launch of Te...
